Full-length publication on the overall survival of “real-life” patients versus patients in clinical trials
“Real-life” patients, such as the patients in the tumour registry of advanced renal cell carcinoma, often do not fulfil the strict inclusion criteria in clinical trials and are therefore considered “trial inappropriate”. An analysis in the tumour registry of renal cell carcinoma showed that this applies to almost 60% of all mRCC patients in clinical routine practice in Germany. Compared to patients from clinical trials the overall survival of “trial inappropriate” patients is clearly lower. The data analysis was recently published in Clinical Genitourinary Cancer.
Numerous publications at the ESMO congress in September
iOMEDICO will be represented at the ESMO congress in Madrid with numerous contributions: […]
Two full publications in one swoop
The relevance of the data from the iOMEDICO tumor registries is highly acknowledged […]
The publications keep on coming
Every year, the data from the tumour registries become more comprehensive, and their […]